Advertisement
You are not currently logged in.
Login
or
Register
Get Email Updates
Patients » Visit TheBody.com
0
Email
FDA-Approved Antiretrovirals
Antiretrovirals Overview
Multi-Class Combinations
Efavirenz/Tenofovir/Emtricitabine (Atripla)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir (Stribild)
Rilpivirine/Tenofovir/Emtricitabine (Complera)
Entry Inhibitors (Fusion, CCR5, etc.)
Enfuvirtide (T-20, Fuzeon)
Maraviroc (Selzentry, Celsentri)
Integrase Inhibitors
Raltegravir (MK-0518, Isentress)
Protease Inhibitors
Atazanavir (Reyataz)
Darunavir (TMC114, Prezista)
Fosamprenavir (Lexiva, Telzir)
Indinavir (Crixivan)
Lopinavir/Ritonavir (Kaletra)
Nelfinavir (Viracept)
Ritonavir (Norvir)
Saquinavir (Invirase)
Tipranavir (Aptivus)
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Abacavir (Ziagen)
Abacavir/Lamivudine (Epzicom, Kivexa)
Didanosine (ddI, Videx)
Emtricitabine (FTC, Emtriva)
Lamivudine (3TC, Epivir)
Stavudine (d4T, Zerit)
Tenofovir (Viread)
Tenofovir/Emtricitabine (Truvada)
Zalcitabine (ddC, Hivid)
Zidovudine (AZT, Retrovir)
Zidovudine/Lamivudine (Combivir)
Zidovudine/Lamivudine/
Abacavir (Trizivir)
Non-Nucleoside Reverse Transcriptase Inhibitors
Delavirdine (Rescriptor)
Efavirenz (Sustiva, Stocrin)
Etravirine (TMC125, Intelence)
Nevirapine (Viramune)
Rilpivirine (Edurant, TMC278)
Antiretrovirals in Development
0
Email
Advertisement
Advertisement
MOST VIEWED ARTICLES
HIV Management Today
: Mental Health & HIV, the Uncharted Territory
10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
CROI 2013: Women's Issues in HIV Research (Video)
Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
HIV Opportunistic Infection Guidelines Updated
More Most Viewed Articles